A practical reference on IGF-1: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-29 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
== Phosphoanhydride bond formation == While early studies of phosphorimidazolide derivatives of nucleotides found that oligonucleotides could form in the presence of a complementary template, pyrophosphate-linked dimers formed predominantly in the absence of a template. This proclivity for forming new phosphoanhydride bonds has been used in the synthesis of several pyrophosphate-containing organic compounds. A variety of modified nucleotide triphosphates were synthesized using a cyanoethyl-protected phosphorimidazolide reagent. Phosphoanhydride bond forming reactions were found to proceed most rapidly in amide-based organic solvents such as N,N-dimethylformamide and particularly in N,N-dimethylacetamide with Mg2+ or Zn2+ catalysts.
== Principle == Delayed neutrons are associated with the beta decay of the fission products. After prompt fission neutron emission the residual fragments are still neutron rich and undergo a beta decay chain. The more neutron rich the fragment, the more energetic and faster the beta decay. In some cases the available energy in the beta decay is high enough to leave the residual nucleus in such a highly excited state that neutron emission instead of gamma emission occurs. Using U-235 as an example, this nucleus absorbs thermal neutrons, and the immediate mass products of a fission event are two large fission fragments, which are remnants of the formed U-236 nucleus. These fragments emit two to three free neutrons (2.43 on average), called "prompt" neutrons. A subsequent fission fragment occasionally undergoes a stage of radioactive decay (which is a beta minus decay) that yields a new nucleus (the emitter nucleus) in an excited state that emits an additional neutron, called a "delayed" neutron, to get to ground state. These neutron-emitting fission fragments are called delayed neutron precursor atoms. The longest-lived groups can be traced to specific decay chains. In about 70% of 87Br beta decays (half-life 55 s), the 87Kr daughter is left in a nuclear state above the 5.4 MeV needed to eject its last neutron; it promptly releases a neutron, ending as stable 86Kr. The neutron emission rate is set by the rate of formation of 87Kr, so the group carries the 55 s half-life of the precursor.
== Selected publications == Drucker, D. J.; Philippe, J; Mojsov, S; Chick, W. L.; Habener, J. F. (1987). "Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line". Proceedings of the National Academy of Sciences of the United States of America. 84 (10): 3434–8. Bibcode:1987PNAS...84.3434D. doi:10.1073/pnas.84.10.3434. PMC 304885. PMID 3033647. Scrocchi, L.S.; Brown, T.J.; Maclusky, N.; Brubaker, P.L.; Auerbach, A.B.; Joyner, A.L.; Drucker, D.J. (1996). "Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene". Nature Medicine. 2 (11): 1254–1258. doi:10.1038/nm1196-1254. PMID 8898756. Drucker, D.J.; Ehrlich, P.; Asa, S. L.; Brubaker, P.L. (1996). "Induction of intestinal epithelial proliferation by glucagon-like peptide 2". Proc Natl Acad Sci U S A. 93 (15): 7911–7916. Bibcode:1996PNAS...93.7911D. doi:10.1073/pnas.93.15.7911. PMC 38848. PMID 38848. Chen, E.; Drucker, D.J. (1997). "Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard". Journal of Biological Chemistry. 272 (7): 4108–15. doi:10.1074/jbc.272.7.4108. PMID 9020121. Drucker, D.J.; Shi, Q.; Crivici, A.; Sumner-Smith, M.; Tavares, W.; Hill, M.; DeForest, L.; Cooper, S.; Brubaker, P.L. (1997). "Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV". Nature Biotechnology. 93 (15): 7911–6. doi:10.1038/nbt0797-673. PMID 9219272.
Sources: en.wikipedia.org
Magnetic resonance imaging (MRI) is considered superior to computed tomography (CT) to visualize soft tissues and can detect about 93% of NF cases. It is especially useful in finding fluid in the deep fascia, which can distinguish between NF and cellulitis. When fluid collects in the deep fascia, or thickening or enhancement with contrast, necrotizing fasciitis should be strongly suspected. However, MRI is much slower than CT and not as widely available. There may also be limitations on its use in patients with kidney problems.
=== Scope of Computer Validation === The definition of validation above discusses production of evidence that a system will meet its specification. This definition does not refer to a computer application or a computer system but to a process. The main implications in this are that validation should cover all aspects of the process including the application, any hardware that the application uses, any interfaces to other systems, the users, training and documentation as well as the management of the system and the validation itself after the system is put into use. The PIC/S guideline (PIC/S 2004) defines this as a 'computer related system'. Much effort is expended within the industry upon validation activities, and several journals are dedicated to both the process and methodology around validation, and the science behind it.
In 2001, Freeman reprised his role of Alex Cross in Along Came a Spider, a sequel to 1997's Kiss the Girls. The film received mixed-to-negative reviews. Susan Wloszczyna of USA Today observed that "Freeman strides with noble authority" but thought the overall film was unmemorable. In 2002, Freeman was cast opposite Ben Affleck in the spy thriller The Sum of All Fears. It is based on Tom Clancy's 1991 novel of the same name, about a plot by an Austrian Neo-Nazi to trigger a nuclear war between the United States and Russia, so that he can establish a fascist superstate in Europe. The Sum of All Fears received moderate reviews, but was a commercial success, grossing $193.9 million worldwide. Next, Freeman starred alongside Ashley Judd and Jim Caviezel in High Crimes (2002), a legal thriller based on Joseph Finder's 1998 novel of the same name. The story follows lawyer Claire (Judd), whose husband (Caviezel) is arrested and placed on trial for the murder of villagers while he was in the Marines. Although several critics were unimpressed with the story, they credited Freeman and Judd for their chemistry and performances. In 2003, Freeman appeared as God in the hit comedy Bruce Almighty with Jim Carrey and Jennifer Aniston. Next, he starred in the science fiction horror Dreamcatcher, adapted from Stephen King's 2001 novel of the same name. The film was a box-office flop, and garnered mostly negative reviews; Dreamcatcher has an approval rating of 28% on review aggregate site Rotten Tomatoes.
Sources: en.wikipedia.org
Debbie Dingell official U.S. House website Debbie Dingell for Congress Biography at the Biographical Directory of the United States Congress Financial information (federal office) at the Federal Election Commission Legislation sponsored at the Library of Congress Profile at Vote Smart Appearances on C-SPAN
Amanita verna, commonly known as the fool's mushroom or the spring destroying angel (see destroying angel), is a deadly poisonous basidiomycete fungus, one of many in the genus Amanita. Occurring in Europe in spring, A. verna associates with various deciduous and coniferous trees. The caps, stipes and gills are all white in colour.
In August 2008, Helton was diagnosed with a degenerative back condition, putting his health and ability to continue play in question. On May 19, 2009, Helton got his 2,000th hit, a single, during an 8–1 road loss to the Atlanta Braves. On July 22, Helton hit his 500th career double in a 4–3 home victory over the Arizona Diamondbacks. He became the 50th player in MLB history to hit 500 career doubles and the fastest to do since 1954. Helton also joined Babe Ruth, Stan Musial, Lou Gehrig and Ted Williams as the only players in MLB history to have at least 500 doubles, 320 home runs and a .325 batting average for a career. On March 11, 2010, Helton signed a two-year, $9.9 million contract extension, which ran through the 2013 season. Helton's degenerative back condition sent him back to the disabled list in July. He returned from the DL in August and hit .256 with 8 home runs and 37 RBI for the season. After the season, Helton said he would return to the Rockies in 2011, dispelling rumors of a possible retirement. On February 15, 2011, Helton announced his intention to play baseball for three more years, preferably for the Rockies. On June 30 he played his 2,000th career game. In 2012, Helton continued to deal with what was by now a chronic health issue. On April 14, he drove a 2-run walk-off home run through heavy rain, the seventh walk-off of his career. On July 13, Helton was placed on the 15-day disabled list due to inflammation in his right hip. He had played 63 games to that point, and was batting .235.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.